Cargando…

Vitexin Possesses Anticonvulsant and Anxiolytic-Like Effects in Murine Animal Models

Different types of epilepsy and forms of pathological anxiety have been described as significant neurological disorders that may exist as comorbidities. Some of those disorders share the association of affected limbic areas/neuropathological triggers as well as the use of drugs for their clinical ma...

Descripción completa

Detalles Bibliográficos
Autores principales: de Oliveira, Denise Dias, da Silva, Cassio Prinholato, Iglesias, Bruno Benincasa, Beleboni, Renê O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431698/
https://www.ncbi.nlm.nih.gov/pubmed/32848784
http://dx.doi.org/10.3389/fphar.2020.01181
_version_ 1783571637016199168
author de Oliveira, Denise Dias
da Silva, Cassio Prinholato
Iglesias, Bruno Benincasa
Beleboni, Renê O.
author_facet de Oliveira, Denise Dias
da Silva, Cassio Prinholato
Iglesias, Bruno Benincasa
Beleboni, Renê O.
author_sort de Oliveira, Denise Dias
collection PubMed
description Different types of epilepsy and forms of pathological anxiety have been described as significant neurological disorders that may exist as comorbidities. Some of those disorders share the association of affected limbic areas/neuropathological triggers as well as the use of drugs for their clinical management. The aim of this work was to investigate the anticonvulsant and anxiolytic properties of the vitexin (apigenin-8-C-glucoside), since this compound is a flavonoid usually found as one of the major constituents in several medicinal plants claimed as anxiolytics and/or anticonvulsants. This investigation was performed by the use of a series of classical murine animal models of chemically induced-seizures and of anxiety-related tests (open-field, elevated plus-maze, and light-dark box tests). Here, we show that the systemic administration of vitexin (1.25; 2.5 and 5 mg/kg; i.p.) exhibited selective protection against chemically-induced seizures. Vitexin did not block seizures evoked by glutamate receptors agonists (NMDA and kainic acid), and it did not interfere with the latencies for these seizures. Conversely, the same treatments protected the animals in a dose-dependent manner against the seizures evoked by the Gabaergic antagonists picrotoxin and PTZ and rise the latency time for the first seizure on non-protected animals. The higher dose of vitexin protected 100% of animals against the tonic-clonic seizures triggered by GABA antagonists. The results from open-field, elevated plus-maze, and light-dark box tests indicated the anxiolytic properties of vitexin at similar range of doses described for the anticonvulsant action screening. Furthermore, these results pointed that vitexin did not cause sedation or locomotor impairment on animals. The selective action of vitexin against picrotoxin and PTZ may reinforce the hypothesis by which this compound acts mainly by the modulation of GABAergic neurotransmission and/or related pathways. This could be useful to explain the dual activity of vitexin as anticonvulsant and anxiolytic, and highlight the pharmacological interest on this promising flavonoid.
format Online
Article
Text
id pubmed-7431698
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74316982020-08-25 Vitexin Possesses Anticonvulsant and Anxiolytic-Like Effects in Murine Animal Models de Oliveira, Denise Dias da Silva, Cassio Prinholato Iglesias, Bruno Benincasa Beleboni, Renê O. Front Pharmacol Pharmacology Different types of epilepsy and forms of pathological anxiety have been described as significant neurological disorders that may exist as comorbidities. Some of those disorders share the association of affected limbic areas/neuropathological triggers as well as the use of drugs for their clinical management. The aim of this work was to investigate the anticonvulsant and anxiolytic properties of the vitexin (apigenin-8-C-glucoside), since this compound is a flavonoid usually found as one of the major constituents in several medicinal plants claimed as anxiolytics and/or anticonvulsants. This investigation was performed by the use of a series of classical murine animal models of chemically induced-seizures and of anxiety-related tests (open-field, elevated plus-maze, and light-dark box tests). Here, we show that the systemic administration of vitexin (1.25; 2.5 and 5 mg/kg; i.p.) exhibited selective protection against chemically-induced seizures. Vitexin did not block seizures evoked by glutamate receptors agonists (NMDA and kainic acid), and it did not interfere with the latencies for these seizures. Conversely, the same treatments protected the animals in a dose-dependent manner against the seizures evoked by the Gabaergic antagonists picrotoxin and PTZ and rise the latency time for the first seizure on non-protected animals. The higher dose of vitexin protected 100% of animals against the tonic-clonic seizures triggered by GABA antagonists. The results from open-field, elevated plus-maze, and light-dark box tests indicated the anxiolytic properties of vitexin at similar range of doses described for the anticonvulsant action screening. Furthermore, these results pointed that vitexin did not cause sedation or locomotor impairment on animals. The selective action of vitexin against picrotoxin and PTZ may reinforce the hypothesis by which this compound acts mainly by the modulation of GABAergic neurotransmission and/or related pathways. This could be useful to explain the dual activity of vitexin as anticonvulsant and anxiolytic, and highlight the pharmacological interest on this promising flavonoid. Frontiers Media S.A. 2020-08-11 /pmc/articles/PMC7431698/ /pubmed/32848784 http://dx.doi.org/10.3389/fphar.2020.01181 Text en Copyright © 2020 de Oliveira, da Silva, Iglesias and Beleboni http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
de Oliveira, Denise Dias
da Silva, Cassio Prinholato
Iglesias, Bruno Benincasa
Beleboni, Renê O.
Vitexin Possesses Anticonvulsant and Anxiolytic-Like Effects in Murine Animal Models
title Vitexin Possesses Anticonvulsant and Anxiolytic-Like Effects in Murine Animal Models
title_full Vitexin Possesses Anticonvulsant and Anxiolytic-Like Effects in Murine Animal Models
title_fullStr Vitexin Possesses Anticonvulsant and Anxiolytic-Like Effects in Murine Animal Models
title_full_unstemmed Vitexin Possesses Anticonvulsant and Anxiolytic-Like Effects in Murine Animal Models
title_short Vitexin Possesses Anticonvulsant and Anxiolytic-Like Effects in Murine Animal Models
title_sort vitexin possesses anticonvulsant and anxiolytic-like effects in murine animal models
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431698/
https://www.ncbi.nlm.nih.gov/pubmed/32848784
http://dx.doi.org/10.3389/fphar.2020.01181
work_keys_str_mv AT deoliveiradenisedias vitexinpossessesanticonvulsantandanxiolyticlikeeffectsinmurineanimalmodels
AT dasilvacassioprinholato vitexinpossessesanticonvulsantandanxiolyticlikeeffectsinmurineanimalmodels
AT iglesiasbrunobenincasa vitexinpossessesanticonvulsantandanxiolyticlikeeffectsinmurineanimalmodels
AT belebonireneo vitexinpossessesanticonvulsantandanxiolyticlikeeffectsinmurineanimalmodels